US Population Eligibility and Estimated Impact of Tirzepatide Treatment on Obesity Prevalence and Cardiovascular Disease Events.

Nathan D WongHridhay KarthikeyanWenjun Fan

Published in: Cardiovascular drugs and therapy (2024)

Tirzepatide treatment in appropriate US adults may substantially reduce obesity prevalence and CVD events, impacting beneficially on associated healthcare costs.

Keyphrases

cardiovascular disease
healthcare
type diabetes
metabolic syndrome
insulin resistance
weight loss
weight gain
body mass index
skeletal muscle
combination therapy
social media
replacement therapy